Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Capital Leases (2016 - 2024)

Historic Capital Leases for Trinity Biotech (TRIB) over the last 9 years, with Q4 2024 value amounting to $10.5 million.

  • Trinity Biotech's Capital Leases fell 363.32% to $10.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $10.5 million, marking a year-over-year decrease of 363.32%. This contributed to the annual value of $10.5 million for FY2024, which is 363.32% down from last year.
  • According to the latest figures from Q4 2024, Trinity Biotech's Capital Leases is $10.5 million, which was down 363.32% from $10.9 million recorded in Q4 2023.
  • In the past 5 years, Trinity Biotech's Capital Leases registered a high of $16.6 million during Q4 2020, and its lowest value of $200000.0 during Q2 2022.
  • For the 5-year period, Trinity Biotech's Capital Leases averaged around $10.7 million, with its median value being $11.6 million (2022).
  • Per our database at Business Quant, Trinity Biotech's Capital Leases crashed by 1641.55% in 2021 and then crashed by 363.32% in 2024.
  • Trinity Biotech's Capital Leases (Quarter) stood at $16.6 million in 2020, then dropped by 16.42% to $13.9 million in 2021, then fell by 11.53% to $12.3 million in 2022, then decreased by 11.37% to $10.9 million in 2023, then decreased by 3.63% to $10.5 million in 2024.
  • Its Capital Leases was $10.5 million in Q4 2024, compared to $10.9 million in Q4 2023 and $12.3 million in Q4 2022.